Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q2 2013 · 10-Q
Revenue$1.96M$1.96M−28.1% vs Q2 2012 Net Income-$301.00K-$301.00KN/M vs Q2 2012 EPS Diluted-$0.01-$0.01— vs Q2 2012 Operating Income-$319,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-16.3%−7.0 pt vs Q2 2012
Net margin-15.4%−10.6 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 1, 2013 · 32 d after period end